CytoReason News
23 articles
Israeli AI disease models co CytoReason raises $80m
Israeli biopharma decision making company CytoReason has completed an $80 million financing round from investors including OurCrowd, Nvidia, Pfizer, and Thermo Fisher Scientific. The company, which develops AI-based computational disease models for predictive insights, plans to use the funds to expand application of its models, grow its proprietary molecular and clinical data, and set up an office in Cambridge, Massachusetts. CytoReasons technology is used by six of the worlds top 10 pharma companies to make data-driven decisions in various therapeutic areas.
InvestmentPartnersExpand
Momentum for Poolbeg and CytoReason's AI collaboration - PharmaTimes
Poolbeg Pharma, a company focusing on infectious diseases, has announced a significant breakthrough in its influenza artificial intelligence (AI) programme with CytoReason. The collaboration has led to the identification of several novel drug targets for treating influenza, achieved by studying disease progression data from influenza human challenge trials using CytoReasons AI-led platform. This process has allowed Poolbeg to identify multiple novel drug targets in just 15 months, marking the companys second successful AI project. The partnership has put Poolbeg at the forefront of AI drug discovery.
Partners
Sanofi extends cooperation with Israel's CytoReason for bowel disease drug discovery
Tel Aviv-based startup CytoReason has extended its cooperation with French drugmaker Sanofi to use its computational disease model platform to predict responses to drugs for patients with inflammatory bowel disease (IBD). Sanofi will pay CytoReason an undisclosed multimillion dollar amount. CytoReasons AI-powered platform will also provide insights on drug development for IBD patients. The global computer-aided drug discovery market is expected to reach over $7.5 billion by 2030. CytoReasons technology uses AI and a massive database to shorten trial phases, cut development costs, and increase the likelihood of drug approval. CytoReason has previously worked with Pfizer, Ferring, Roche, and GSK.
Partners
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform | CTech
Pfizer has extended its partnership with CytoReason, an Israeli startup, to use its artificial intelligence technology for Pfizers drug development programs. As part of the agreement, Pfizer will make a $20 million equity investment and have options to license CytoReasons platform and disease models. The deal is potentially worth up to $110 million over the next five years. Since the collaboration began in 2019, Pfizer has utilized CytoReasons biological models to enhance its understanding of the immune system and develop innovative drugs for immune-mediated and immuno-oncology diseases. The new research agreement and investment will support the development of additional disease models and high-resolution models in various therapeutic areas.
PartnersInvestment
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
CytoReason has signed a commercial partnership with Helixrus, a Korean company focused on biological big data and multi-omics. The partnership aims to promote CytoReasons AI platform and professional services in the Korean market. CytoReasons computational disease models have gained recognition globally, and the alliance with Helixrus will leverage their knowledge of the Korean pharmaceutical market. CytoReason already collaborates with major pharmaceutical companies and aims to establish its technology as the gold standard for drug discovery and development. Helixrus will provide software and bioscience offerings to accelerate discovery in the expanding Korean biopharma market.
Partners
Pfizer extends cooperation deal with Israeli AI drug development firm CytoReason
Pharmaceutical giant Pfizer has extended its collaboration with Israeli company CytoReason, a developer of computational disease models for drug discovery. The collaboration aims to use CytoReasons digital models of the human immune system and diseases to inform Pfizers development of innovative drugs. CytoReasons technology allows pharmaceutical companies to simulate drug responses using AI, reducing costs and time in the drug discovery process. The extended partnership with CytoReason will enhance Pfizers data-driven decision-making capabilities and potentially lead to the development of new therapies. CytoReason has also worked with other global pharmaceutical companies, including Sanofi, Ferring, Roche, and GSK.
Partners
סייטוריזן פיתחה תוכנת AI המנבאת הצלחה של ניסויים קליניים - Techtime - חדשות אלקטרוניקה והייטק
CytoReason, an artificial intelligence company focused on drug development, has raised $9.3 million in funding led by OurCrowd and other investors. The companys platform uses molecular data to predict the success of clinical trials and optimize drug development. The algorithm can identify the most effective molecule for treating a specific disease and predict patient response to the drug. CytoReason has partnered with six of the top 10 pharmaceutical companies and specializes in modeling immune system activity. The funding will help accelerate the companys complex drug development processes.
Investment
Merck KGaA taps CytoReason's machine learning platform to profile immuno-oncology drug
The article does not provide any information about Questex LLC or any specific events related to the company.
CytoReason, Summit tap into AI on Japanese drug development effort
CytoReason has announced a partnership with Summit Pharmaceuticals International to provide AI-based technology for drug development. The collaboration aims to advance understanding of how drugs behave on a molecular level. CytoReasons computational disease models, combined with clinical data from the pharmaceutical company, will help make data-driven decisions in drug programs. This partnership marks CytoReasons expansion into the Japanese market.
Partners
CytoReason enters Japanese market with SPI partnership
CytoReason, an Israeli company specializing in AI-driven clinical drug development, has announced a collaboration with Summit Pharmaceuticals International (SPI), a Japanese pharmaceutical company. This marks the first collaboration between an Israeli and Japanese company in bringing AI to clinical drug development. CytoReasons AI platform will be used to gain a better understanding of how drugs behave on molecular levels. The collaboration aims to explore the relationship between disease mechanisms and drug mechanisms of action (MoA) to increase the valuation of drugs in immunology. The partnership signifies a meaningful step forward for CytoReason and the global pharmaceutical industry. SPI is a wholly-owned subsidiary of Sumitomo Corporation. CytoReason has raised $10 million in Series A funding led by PICO Venture Partners and Pontifax.
Partners
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
CytoReason has announced a collaboration project with Sanofi to gain clarity on the heterogeneity of asthma patients and identify stable and reproducible asthma endotypes. CytoReasons AI platform will utilize comprehensive datasets to suggest mechanistic insights for each asthma endotype. The goal is to inform precision medicine strategies for improved patient benefit. The collaboration represents an opportunity to drive better understanding of the complex nature of asthma and enhance future research in the field. CytoReasons computational model of the human body simulates human disease on a cellular level, minimizing the need for animal trials and making human trials more focused and accurate.
Partners
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
CytoReason announces a collaboration with Ferring Pharmaceuticals to establish new treatment options for patients with inflammatory bowel disease (IBD). CytoReasons computational model of the human body will be paired with Ferrings medical expertise to build cell-centered disease models. The collaboration aims to accelerate drug discovery for IBD and provide new therapeutic options for patients. CytoReasons technology allows scientists to gain critical information on the bodys functioning and address diseases such as IBD at the cellular level. This collaboration is expected to shorten drug discovery time, reduce costs, and benefit more patients suffering from IBD.
Partners
The secret Israeli sauce in Pfizer's new drug mix - Sponsored Content The Times of Israel
Pharmaceutical giant Pfizer has partnered with Israeli startup CytoReason to use its artificial intelligence-powered platform to accelerate the development of new drugs. CytoReasons technology builds digital models of the human immune system and diseases, allowing Pfizer to quickly narrow down the potential uses of its drugs. The platform can replace some animal trials, saving time and costs. Other pharmaceutical companies, including GlaxoSmithKline and Roche, are also using CytoReasons technology. The future of drug development is expected to rely heavily on models and data from companies like CytoReason, potentially replacing lengthy trials and lab work. The cost of developing new drugs is rising, and companies are looking for more cost-effective ways to develop life-saving medications.
Partners
AI-Powered Drug Development in a Post-COVID World
When can computer models replace animal trials? - Drug Discovery and Development
The article discusses the use of computer modeling as an alternative to animal testing in the pharmaceutical industry. CytoReason, led by CEO David Harel, is at the forefront of developing computer models that can generate better predictions than animal models for certain diseases. Computer models are seen as a more humane, faster, cheaper, and more accurate alternative to animal studies. However, there are challenges in obtaining non-animal data for modeling human diseases. The field of regulatory affairs and the embrace of cloud computing are helping to simplify data sharing and aggregation. The COVID-19 pandemic has also led to increased flexibility from regulators, with the FDA approving an efficacy trial based on computer simulations without animal models. The article suggests that the pandemic could further drive the adoption of computer models in drug development.
Customers
New Startup Helps Pfizer Create More Effective, Targeted Drugs For Patients - The Tennessee Tribune
Israeli startup CytoReason will help Pfizer develop the next generation of drugs more efficiently and effectively using its machine-learning platform. CytoReasons platform aggregates data from various sources to provide insights into the biology of autoimmune diseases, suggest new drug targets, and identify patients who may benefit the most from certain medicines. The partnership has growth-positive impact on Pfizer. CytoReason has relationships with three of the worlds largest pharmaceutical companies and has collaborated with GlaxoSmithKline and the Parker Institute for Cancer Immunotherapy. The startup was founded in 2016 and has yielded patents, collaborations, and publications.
Partners
https://www.jpost.com/opinion/hillels-tech-corner-cytoreason-where-ai-meets-drug-development-631184
The article discusses CytoReason, a Tel Aviv based company that aims to leverage new technology to address the complexity and costs of bringing new therapies to market. CytoReason uses proprietary data derived from human clinical trials and machine learning technology to build an understanding of disease biology and simulate the effects of drug treatments. The company has collaborations with Pfizer, GlaxoSmithKline, and the Parker Institute for Cancer Immunotherapy. CytoReasons technology has yielded patents, collaborations, and publications in various fields. The article highlights the need for better tools and technology to predict treatment effectiveness and accelerate drug development. The author expresses optimism about CytoReasons potential breakthroughs in improving health outcomes.
PartnersCustomers
סייטוריזון בנבחרת הסטארטאפים 2020 של TheMarker
CytoReason, a biotech company, has developed a machine learning engine that helps pharmaceutical companies better understand the behavior of drugs and diseases, and optimize their clinical trials. The company has raised an estimated $5 million in funding from private investors and the PICO fund. CytoReason has a team of 55 employees, with 45 in Israel. The article highlights the potential of CytoReasons technology in revolutionizing drug development and improving the efficiency of clinical trials.
Investment
Ground Breaking New Methodology Published in Nature Medicine Uncovers the Missing Numbers to the Only Clock That Really Matters in the Body - Your Immune Age
Scientists at the Technion, Stanford, and CytoReason have developed a way to quantify a persons immune age, which could have significant implications for drug and vaccine development. The new metric, called IMM-AGE, provides a more reliable predictor of immune status and could lead to improved clinical trial entry criteria and greater success in drug development programs. The researchers followed a group of healthy volunteers for nine years, taking annual blood samples and analyzing them using machine learning analytical technologies. The data and metrics were validated against a cohort of over 2,000 patients. CytoReason, the company involved in the research, uses proprietary data and machine learning models to reconstruct cellular information and generate mechanistic understanding of the immune system.
Investment
CytoReason teams with Pfizer on drug discovery
Israeli machine learning company CytoReason has entered into a collaboration agreement with Pfizer. Under the agreement, Pfizer will pay CytoReason over $10 million for technology access fees, research support, and success-based payments. CytoReasons platform helps rebuild lost cellular information from gene expression data and creates a cell-based model of the immune response. The collaboration with Pfizer will strengthen CytoReasons models in its core therapeutic areas. This is CytoReasons fifth major partnership and will enhance its accuracy for assets across the pipeline.
Partners
CytoReason builds largest reference of immune-focused inter-cellular communications
New data published in Nature Biotechnology reveals the largest ever analysis of immune cell signaling research, mapping previously unlisted cellular interactions and yielding the first ever immune-centric modular classification of diseases. The data serves to rewrite the reference book on immune-focused inter-cellular communications and disease relationships. The study highlights the complexity and diversity of the immune system and emphasizes the need for machine learning methods to fully leverage the advancements in immunology and science. Standardizing and contextualizing cell-cytokine relationships is crucial for broadening our understanding of the immune system. The study demonstrates the potential of integrating curated knowledge with other data sources and AI technologies to generate new insights in disease research.
Customers
CytoReason uses AI to personalize drugs, opening the door to cancer treatments
CytoReason, an AI company based in Tel Aviv, has discovered a unique biomarker that can predict the response to anti-TNF drugs. Using AI models of the immune system, CytoReason identified specific biomarkers in blood and tissue samples that can determine who will respond to these drugs. The biomarkers were validated with high accuracy rates. CytoReason is also using AI to accelerate the identification of the efficacy of other therapies. AI is changing the landscape of clinical trials, allowing for shorter and less expensive trials. However, AI does not replace the need for validation through laboratory testing or trials. CytoReason plans to expand its AI platform to discover biomarkers in other types of treatments.
PartnersCustomers
CytoReason Signs Collaboration Agreement with Pfizer Inc. To Utilize CytoReason's Machine Learning Model of the Immune System for Drug Discovery
CytoReason has entered into a collaboration agreement with Pfizer Inc. The collaboration will leverage CytoReasons cell-centered models of the immune system. CytoReason will receive payments potentially equaling up to low double digit millions of US$ for technology access fees, research support, and success-based payments. The collaboration will strengthen CytoReasons models in its core therapeutic areas and make its model unparalleled in accuracy for assets across the pipeline.
Partners
